{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:12:16Z","timestamp":1765483936263,"version":"build-2065373602"},"reference-count":175,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":3247,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s13311-014-0284-z","type":"journal-article","created":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T11:10:26Z","timestamp":1403521826000},"page":"738-750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Heterogeneity of Leucine-Rich Repeat Kinase 2 Mutations: Genetics, Mechanisms and Therapeutic Implications"],"prefix":"10.1016","volume":"11","author":[{"given":"Iakov N.","family":"Rudenko","sequence":"first","affiliation":[]},{"given":"Mark R.","family":"Cookson","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1007\/s13311-014-0284-z_bib1","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","article-title":"Parkinson's disease","volume":"373","author":"Lees","year":"2009","journal-title":"Lancet"},{"key":"10.1007\/s13311-014-0284-z_bib2","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/mds.23669","article-title":"Milestones in Parkinson's disease\u2014clinical and pathologic features","volume":"26","author":"Halliday","year":"2011","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-014-0284-z_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mds.25249","article-title":"The genetics of Parkinson's disease: progress and therapeutic implications","volume":"28","author":"Singleton","year":"2013","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-014-0284-z_bib4","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/ng.487","article-title":"Genome-wide association study reveals genetic risk underlying Parkinson's disease","volume":"41","author":"Sim\u00f3n-S\u00e1nchez","year":"2009","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-014-0284-z_bib5","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ng.485","article-title":"Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease","volume":"41","author":"Satake","year":"2009","journal-title":"Nat Genet"},{"issue":"Suppl. 3","key":"10.1007\/s13311-014-0284-z_bib6","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.1016\/S1353-8020(09)70815-6","article-title":"Clinical features of LRRK2 parkinsonism","volume":"15","author":"Haugarvoll","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-014-0284-z_bib7","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","article-title":"Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study","volume":"7","author":"Healy","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-014-0284-z_bib8","first-page":"217","article-title":"Genetic neuropathology of Parkinson's disease","volume":"1","author":"Cookson","year":"2008","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1007\/s13311-014-0284-z_bib9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","article-title":"Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease","volume":"44","author":"Paisan-Ruiz","year":"2004","journal-title":"Neuron"},{"key":"10.1007\/s13311-014-0284-z_bib10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron"},{"key":"10.1007\/s13311-014-0284-z_bib11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ana.10113","article-title":"A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1","volume":"51","author":"Funayama","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-014-0284-z_bib12","doi-asserted-by":"crossref","first-page":"16842","DOI":"10.1073\/pnas.0507360102","article-title":"Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity","volume":"102","author":"West","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-014-0284-z_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.nbd.2006.04.001","article-title":"Kinase activity is required for the toxic effects of mutant LRRK2\/dardarin","volume":"23","author":"Greggio","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-014-0284-z_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/hmg\/ddi439","article-title":"The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity","volume":"15","author":"Gloeckner","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0284-z_bib15","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/nn1776","article-title":"Kinase activity of mutant LRRK2 mediates neuronal toxicity","volume":"9","author":"Smith","year":"2006","journal-title":"Nat Neurosci"},{"key":"10.1007\/s13311-014-0284-z_bib16","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1051\/medsci\/200521121015","article-title":"LRRK2: a gene belonging to the ROCO family is implicated in the Parkinson's disease","volume":"21","author":"Lesage","year":"2005","journal-title":"Med Sci (Paris)"},{"key":"10.1007\/s13311-014-0284-z_bib17","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1093\/molbev\/msl114","article-title":"The Parkinson disease gene LRRK2: evolutionary and structural insights","volume":"23","author":"Marin","year":"2006","journal-title":"Mol Biol Evol"},{"key":"10.1007\/s13311-014-0284-z_bib18","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.bbrc.2007.04.006","article-title":"The R1441C mutation of LRRK2 disrupts GTP hydrolysis","volume":"357","author":"Lewis","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1007\/s13311-014-0284-z_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1471-4159.2007.04743.x","article-title":"Leucine-rich repeat kinase 2 (LRRK2)\/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C\/G mutants","volume":"103","author":"Li","year":"2007","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-014-0284-z_bib20","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.yexcr.2007.07.007","article-title":"The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity","volume":"313","author":"Guo","year":"2007","journal-title":"Exp Cell Res"},{"key":"10.1007\/s13311-014-0284-z_bib21","doi-asserted-by":"crossref","first-page":"e23207","DOI":"10.1371\/journal.pone.0023207","article-title":"LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding","volume":"6","author":"Taymans","year":"2011","journal-title":"PLoS One"},{"key":"10.1007\/s13311-014-0284-z_bib22","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1021\/bi901851y","article-title":"Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities","volume":"49","author":"Liu","year":"2010","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-014-0284-z_bib23","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1021\/bi061960m","article-title":"GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease","volume":"46","author":"Ito","year":"2007","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-014-0284-z_bib24","doi-asserted-by":"crossref","first-page":"16906","DOI":"10.1074\/jbc.M708718200","article-title":"The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation","volume":"283","author":"Greggio","year":"2008","journal-title":"J Biol Chem."},{"key":"10.1007\/s13311-014-0284-z_bib25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbrc.2009.08.163","article-title":"The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites","volume":"389","author":"Greggio","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1007\/s13311-014-0284-z_bib26","doi-asserted-by":"crossref","first-page":"10963","DOI":"10.1021\/bi9011379","article-title":"Identification of the autophosphorylation sites of LRRK2","volume":"48","author":"Kamikawaji","year":"2009","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-014-0284-z_bib27","doi-asserted-by":"crossref","first-page":"29569","DOI":"10.1074\/jbc.M110.127639","article-title":"Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2","volume":"285","author":"Li","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-014-0284-z_bib28","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1021\/pr9008578","article-title":"Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2","volume":"9","author":"Gloeckner","year":"2010","journal-title":"J Proteome Res"},{"key":"10.1007\/s13311-014-0284-z_bib29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jmb.2011.07.033","article-title":"Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities","volume":"412","author":"Webber","year":"2011","journal-title":"J Mol Biol"},{"key":"10.1007\/s13311-014-0284-z_bib30","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1042\/BST20120133","article-title":"The GTPase function of LRRK2","volume":"40","author":"Taymans","year":"2012","journal-title":"Biochem Soc Trans"},{"key":"10.1007\/s13311-014-0284-z_bib31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.tins.2006.03.006","article-title":"LRRK2 in Parkinson's disease: protein domains and functional insights","volume":"29","author":"Mata","year":"2006","journal-title":"Trends Neurosci"},{"key":"10.1007\/s13311-014-0284-z_bib32","doi-asserted-by":"crossref","first-page":"e13762","DOI":"10.1371\/journal.pone.0013762","article-title":"ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2","volume":"5","author":"Haebig","year":"2010","journal-title":"PLoS One"},{"key":"10.1007\/s13311-014-0284-z_bib33","doi-asserted-by":"crossref","first-page":"e1002526","DOI":"10.1371\/journal.pgen.1002526","article-title":"GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1","volume":"8","author":"Stafa","year":"2012","journal-title":"PLoS Genet"},{"key":"10.1007\/s13311-014-0284-z_bib34","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1523\/JNEUROSCI.4566-11.2012","article-title":"ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2","volume":"32","author":"Xiong","year":"2012","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-014-0284-z_bib35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11910-012-0265-8","article-title":"Mechanisms of LRRK2-mediated neurodegeneration","volume":"12","author":"Tsika","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1007\/s13311-014-0284-z_bib36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrm2689","article-title":"It takes two to tango - regulation of G proteins by dimerization","volume":"10","author":"Gasper","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1007\/s13311-014-0284-z_bib37","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1021\/bi100157u","article-title":"Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation","volume":"49","author":"Berger","year":"2010","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-014-0284-z_bib38","doi-asserted-by":"crossref","first-page":"36346","DOI":"10.1074\/jbc.M109.025437","article-title":"Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization","volume":"284","author":"Sen","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-014-0284-z_bib39","doi-asserted-by":"crossref","first-page":"e43472","DOI":"10.1371\/journal.pone.0043472","article-title":"Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers","volume":"7","author":"Civiero","year":"2012","journal-title":"PLoS One"},{"key":"10.1007\/s13311-014-0284-z_bib40","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/jnr.21622","article-title":"The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules","volume":"86","author":"Gandhi","year":"2008","journal-title":"J Neurosci Res"},{"key":"10.1007\/s13311-014-0284-z_bib41","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/hmg\/ddr526","article-title":"LRRK2 Parkinson disease mutations enhance its microtubule association","volume":"21","author":"Kett","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0284-z_bib42","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.nbd.2012.12.019","article-title":"Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration","volume":"54","author":"Caesar","year":"2013","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-014-0284-z_bib43","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/j.1471-4159.2009.06235.x","article-title":"Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability\u2013a point of convergence in parkinsonian neurodegeneration?","volume":"110","author":"Gillardon","year":"2009","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-014-0284-z_bib44","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1042\/BJ20100483","article-title":"14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization","volume":"430","author":"Nichols","year":"2010","journal-title":"Biochem J"},{"key":"10.1007\/s13311-014-0284-z_bib45","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1042\/BJ20100784","article-title":"Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)\/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization","volume":"430","author":"Dzamko","year":"2010","journal-title":"Biochem J"},{"key":"10.1007\/s13311-014-0284-z_bib46","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/j.1471-4159.2010.06568.x","article-title":"MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2","volume":"112","author":"Hsu","year":"2010","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-014-0284-z_bib47","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1093\/hmg\/ddp337","article-title":"Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways","volume":"18","author":"Sancho","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0284-z_bib48","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nrn2935","article-title":"The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease","volume":"11","author":"Cookson","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"10.1007\/s13311-014-0284-z_bib49","doi-asserted-by":"crossref","first-page":"9879","DOI":"10.1073\/pnas.1004676107","article-title":"Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice","volume":"107","author":"Tong","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-014-0284-z_bib50","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1093\/hmg\/ddr348","article-title":"LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice","volume":"20","author":"Herzig","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0284-z_bib51","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.neuron.2012.11.033","article-title":"RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk","volume":"77","author":"MacLeod","year":"2013","journal-title":"Neuron"},{"key":"10.1007\/s13311-014-0284-z_bib52","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1523\/JNEUROSCI.3730-10.2011","article-title":"LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool","volume":"31","author":"Piccoli","year":"2011","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-014-0284-z_bib53","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.nbd.2010.07.010","article-title":"Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice","volume":"40","author":"Melrose","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-014-0284-z_bib54","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1523\/JNEUROSCI.5604-09.2010","article-title":"Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S","volume":"30","author":"Li","year":"2010","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-014-0284-z_bib55","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nn.3636","article-title":"LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity","volume":"17","author":"Parisiadou","year":"2014","journal-title":"Nat Neurosci"},{"key":"10.1007\/s13311-014-0284-z_bib56","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.neuron.2006.10.008","article-title":"The familial Parkinsonism gene LRRK2 regulates neurite process morphology","volume":"52","author":"MacLeod","year":"2006","journal-title":"Neuron"},{"key":"10.1007\/s13311-014-0284-z_bib57","doi-asserted-by":"crossref","first-page":"13971","DOI":"10.1523\/JNEUROSCI.3799-09.2009","article-title":"Phosphorylation of ezrin\/radixin\/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis","volume":"29","author":"Parisiadou","year":"2009","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-014-0284-z_bib58","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/mds.23265","article-title":"Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease","volume":"25","author":"Aasly","year":"2010","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-014-0284-z_bib59","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1017\/S1462399409001148","article-title":"Molecular pathogenesis of Parkinson disease: insights from genetic studies","volume":"11","author":"Gasser","year":"2009","journal-title":"Expert Rev Mol Med"},{"key":"10.1007\/s13311-014-0284-z_bib60","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1136\/jmg.2005.035568","article-title":"The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor","volume":"42","author":"Goldwurm","year":"2005","journal-title":"J Med Genet"},{"key":"10.1007\/s13311-014-0284-z_bib61","first-page":"415","article-title":"A common LRRK2 mutation in idiopathic Parkinson's disease","volume":"365","author":"Gilks","year":"2005","journal-title":"Lancet"},{"key":"10.1007\/s13311-014-0284-z_bib62","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.neulet.2005.10.083","article-title":"LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease","volume":"395","author":"Infante","year":"2006","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-014-0284-z_bib63","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/mds.20682","article-title":"G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort","volume":"20","author":"Bras","year":"2005","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-014-0284-z_bib64","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMc055509","article-title":"LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews","volume":"354","author":"Ozelius","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-014-0284-z_bib65","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMc055540","article-title":"LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs","volume":"354","author":"Lesage","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-014-0284-z_bib66","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1021\/bi3012077","article-title":"Type II Kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S","volume":"12","author":"Liu","year":"2013","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-014-0284-z_bib67","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1042\/BJ20070209","article-title":"LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity","volume":"405","author":"Jaleel","year":"2007","journal-title":"Biochem J"},{"key":"10.1007\/s13311-014-0284-z_bib68","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1742-4658.2008.06789.x","article-title":"Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays","volume":"276","author":"Anand","year":"2009","journal-title":"FEBS J"},{"key":"10.1007\/s13311-014-0284-z_bib69","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/hmg\/ddm151","article-title":"Rubio de la Torre E, Delgado A, Perez-Tur J, Hilfiker S. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation","volume":"16","author":"Luzon-Toro","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0284-z_bib70","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/hmg\/ddm080","article-title":"Apoptotic mechanisms in mutant LRRK2-mediated cell death","volume":"16","author":"Iaccarino","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0284-z_bib71","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbrc.2008.11.048","article-title":"Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2","volume":"378","author":"Covy","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1007\/s13311-014-0284-z_bib72","doi-asserted-by":"crossref","first-page":"e8730","DOI":"10.1371\/journal.pone.0008730","article-title":"The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation","volume":"5","author":"Kumar","year":"2010","journal-title":"PLoS One"},{"key":"10.1007\/s13311-014-0284-z_bib73","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1042\/BJ20120637","article-title":"The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation","volume":"446","author":"Rudenko","year":"2012","journal-title":"Biochem J"},{"key":"10.1007\/s13311-014-0284-z_bib74","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ana.20484","article-title":"An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family","volume":"57","author":"Funayama","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-014-0284-z_bib75","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1038\/emboj.2008.163","article-title":"Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila","volume":"17","author":"Imai","year":"2008","journal-title":"EMBO J"},{"key":"10.1007\/s13311-014-0284-z_bib76","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.1021\/bi400596m","article-title":"Differential effects of familial Parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation","volume":"52","author":"Kamikawaji","year":"2013","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-014-0284-z_bib77","doi-asserted-by":"crossref","first-page":"13042","DOI":"10.1074\/jbc.M113.537811","article-title":"The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity","volume":"289","author":"Ray","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-014-0284-z_bib78","doi-asserted-by":"crossref","DOI":"10.1042\/AN20090007","article-title":"Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions","volume":"1","author":"Greggio","year":"2009","journal-title":"ASN Neuro"},{"key":"10.1007\/s13311-014-0284-z_bib79","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1212\/01.wnl.0000304044.22253.03","article-title":"Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease","volume":"70","author":"Haugarvoll","year":"2008","journal-title":"Neurology"},{"key":"10.1007\/s13311-014-0284-z_bib80","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/mds.21114","article-title":"Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques","volume":"21","author":"Simon-Sanchez","year":"2006","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-014-0284-z_bib81","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10048-005-0005-1","article-title":"Lrrk2 pathogenic substitutions in Parkinson's disease","volume":"6","author":"Mata","year":"2005","journal-title":"Neurogenetics"},{"key":"10.1007\/s13311-014-0284-z_bib82","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1212\/01.WNL.0000172630.22804.73","article-title":"A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations","volume":"65","author":"Zabetian","year":"2005","journal-title":"Neurology"},{"key":"10.1007\/s13311-014-0284-z_bib83","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1212\/01.wnl.0000239829.33936.73","article-title":"LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP","volume":"67","author":"Spanaki","year":"2006","journal-title":"Neurology"},{"key":"10.1007\/s13311-014-0284-z_bib84","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.parkreldis.2008.09.001","article-title":"Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism","volume":"15","author":"Ross","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-014-0284-z_bib85","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.parkreldis.2013.05.003","article-title":"Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants","volume":"19","author":"Zhang","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-014-0284-z_bib86","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.parkreldis.2013.01.020","article-title":"Monogenic Parkinson's disease and parkinsonism: clinical phenotypes and frequencies of known mutations","volume":"19","author":"Puschmann","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-014-0284-z_bib87","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1073\/pnas.0709098105","article-title":"Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase","volume":"105","author":"Deng","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-014-0284-z_bib88","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1471-4159.2010.07105.x","article-title":"Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant","volume":"116","author":"Daniels","year":"2011","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-014-0284-z_bib89","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1073\/pnas.1323285111","article-title":"Parkinson disease-associated mutation R1441H in LRRK2 prolongs the \u201cactive state\u201d of its GTPase domain","volume":"111","author":"Liao","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-014-0284-z_bib90","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.bbadis.2009.09.010","article-title":"The R1441C mutation alters the folding properties of the ROC domain of LRRK2","volume":"1792","author":"Li","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1007\/s13311-014-0284-z_bib91","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/emboj.2008.150","article-title":"Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase","volume":"27","author":"Gotthardt","year":"2008","journal-title":"EMBO J"},{"key":"10.1007\/s13311-014-0284-z_bib92","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1042\/BJ20121772","article-title":"Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle","volume":"456","author":"Lobbestael","year":"2013","journal-title":"Biochem J"},{"key":"10.1007\/s13311-014-0284-z_bib93","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.parkreldis.2009.10.004","article-title":"The LRRK2 G2385R variant is a risk factor for sporadic Parkinson's disease in the Korean population","volume":"16","author":"Kim","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-014-0284-z_bib94","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00439-006-0268-0","article-title":"The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence","volume":"120","author":"Tan","year":"2007","journal-title":"Hum Genet"},{"key":"10.1007\/s13311-014-0284-z_bib95","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.parkreldis.2012.08.007","article-title":"LRRK2 G2385R and LRRK2 R1628P increase risk of Parkinson's disease in a Han Chinese population from Southern Mainland China","volume":"19","author":"Fu","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-014-0284-z_bib96","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1471-2377-6-47","article-title":"A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan","volume":"6","author":"Fung","year":"2006","journal-title":"BMC Neurol"},{"key":"10.1007\/s13311-014-0284-z_bib97","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/WNR.0b013e32801254b6","article-title":"Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population","volume":"18","author":"Funayama","year":"2007","journal-title":"Neuroreport"},{"key":"10.1007\/s13311-014-0284-z_bib98","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ana.21405","article-title":"Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease","volume":"64","author":"Ross","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-014-0284-z_bib99","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00439-008-0544-2","article-title":"LRRK2 R1628P increases risk of Parkinson's disease: replication evidence","volume":"124","author":"Tan","year":"2008","journal-title":"Hum Genet"},{"key":"10.1007\/s13311-014-0284-z_bib100","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.brainres.2009.08.047","article-title":"LRRK2 R1628P contributes to Parkinson's disease susceptibility in Chinese Han populations from mainland China","volume":"1296","author":"Yu","year":"2009","journal-title":"Brain Res"},{"key":"10.1007\/s13311-014-0284-z_bib101","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1002\/mds.22371","article-title":"LRRK2 R1628P variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China","volume":"24","author":"Zhang","year":"2009","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-014-0284-z_bib102","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S1474-4422(11)70175-2","article-title":"Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case\u2013control study","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-014-0284-z_bib103","doi-asserted-by":"crossref","first-page":"e8463","DOI":"10.1371\/journal.pone.0008463","article-title":"The WD40 domain is required for LRRK2 neurotoxicity","volume":"4","author":"Jorgensen","year":"2009","journal-title":"PLoS One"},{"key":"10.1007\/s13311-014-0284-z_bib104","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.parkreldis.2011.11.019","article-title":"First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation","volume":"18","author":"Puschmann","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-014-0284-z_bib105","doi-asserted-by":"crossref","first-page":"164ra1","DOI":"10.1126\/scitranslmed.3004485","article-title":"Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations","volume":"4","author":"Sheng","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1007\/s13311-014-0284-z_bib106","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.parkreldis.2010.11.012","article-title":"LRRK2 R1398H polymorphism is associated with decreased risk of Parkinson's disease in a Han Chinese population","volume":"17","author":"Chen","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-014-0284-z_bib107","first-page":"561","article-title":"Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study","volume":"31","author":"Tan","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1007\/s13311-014-0284-z_bib108","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/humu.22075","article-title":"Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe","volume":"33","author":"Rubio","year":"2012","journal-title":"Hum Mutat"},{"issue":"266","key":"10.1007\/s13311-014-0284-z_bib109","first-page":"e5","article-title":"The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants","volume":"35","author":"Heckman","year":"2014","journal-title":"Neurobiol Aging"},{"key":"10.1007\/s13311-014-0284-z_bib110","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/hmg\/dds522","article-title":"GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2","volume":"22","author":"Biosa","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0284-z_bib111","doi-asserted-by":"crossref","first-page":"e1000902","DOI":"10.1371\/journal.pgen.1000902","article-title":"GTPase activity plays a key role in the pathobiology of LRRK2","volume":"6","author":"Xiong","year":"2010","journal-title":"PLoS Genet"},{"key":"10.1007\/s13311-014-0284-z_bib112","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1523\/JNEUROSCI.2712-13.2014","article-title":"Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies","volume":"34","author":"Skibinski","year":"2014","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-014-0284-z_bib113","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nm.2199","article-title":"Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease","volume":"16","author":"Lee","year":"2010","journal-title":"Nat Med"},{"key":"10.1007\/s13311-014-0284-z_bib114","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1073\/pnas.0708452105","article-title":"A Drosophila model for LRRK2-linked parkinsonism","volume":"105","author":"Liu","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-014-0284-z_bib115","doi-asserted-by":"crossref","first-page":"13138","DOI":"10.1523\/JNEUROSCI.1737-10.2010","article-title":"LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ss","volume":"30","author":"Lin","year":"2010","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-014-0284-z_bib116","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1093\/hmg\/ddr312","article-title":"Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models","volume":"20","author":"Liu","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0284-z_bib117","doi-asserted-by":"crossref","first-page":"11257","DOI":"10.1523\/JNEUROSCI.2375-09.2009","article-title":"Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila","volume":"29","author":"Ng","year":"2009","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-014-0284-z_bib118","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cell.2014.01.064","article-title":"Ribosomal protein s15 phosphorylation mediates lrrk2 neurodegeneration in Parkinson's disease","volume":"157","author":"Martin","year":"2014","journal-title":"Cell"},{"key":"10.1007\/s13311-014-0284-z_bib119","doi-asserted-by":"crossref","first-page":"e47784","DOI":"10.1371\/journal.pone.0047784","article-title":"Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations","volume":"7","author":"Trancikova","year":"2012","journal-title":"PLoS One"},{"key":"10.1007\/s13311-014-0284-z_bib120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.nbd.2010.04.002","article-title":"LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease","volume":"40","author":"Yao","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-014-0284-z_bib121","doi-asserted-by":"crossref","first-page":"9210","DOI":"10.1523\/JNEUROSCI.2281-09.2009","article-title":"LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans","volume":"29","author":"Saha","year":"2009","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-014-0284-z_bib122","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1093\/hmg\/ddp394","article-title":"Leucine-rich repeat kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease","volume":"18","author":"Venderova","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0284-z_bib123","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1523\/JNEUROSCI.5092-10.2011","article-title":"A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2","volume":"31","author":"Dusonchet","year":"2011","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-014-0284-z_bib124","doi-asserted-by":"crossref","first-page":"e18568","DOI":"10.1371\/journal.pone.0018568","article-title":"Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2","volume":"6","author":"Ramonet","year":"2011","journal-title":"PLoS One"},{"key":"10.1007\/s13311-014-0284-z_bib125","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/cdd.2012.42","article-title":"(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD","volume":"19","author":"Chen","year":"2012","journal-title":"Cell Death Differ"},{"key":"10.1007\/s13311-014-0284-z_bib126","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1750-1326-7-15","article-title":"The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities","volume":"7","author":"Maekawa","year":"2012","journal-title":"Mol Neurodegener"},{"key":"10.1007\/s13311-014-0284-z_bib127","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nn.2349","article-title":"Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease","volume":"12","author":"Li","year":"2009","journal-title":"Nat Neurosci"},{"key":"10.1007\/s13311-014-0284-z_bib128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neulet.2013.05.034","article-title":"Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R(1)(4)(4)(1)G) transgenic mouse","volume":"549","author":"Dranka","year":"2013","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-014-0284-z_bib129","doi-asserted-by":"crossref","first-page":"14622","DOI":"10.1073\/pnas.0906334106","article-title":"R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice","volume":"106","author":"Tong","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-014-0284-z_bib130","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.brainres.2007.04.034","article-title":"Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain","volume":"1155","author":"Higashi","year":"2007","journal-title":"Brain Res"},{"key":"10.1007\/s13311-014-0284-z_bib131","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1471-4159.2006.04246.x","article-title":"Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain","volume":"100","author":"Higashi","year":"2007","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-014-0284-z_bib132","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/ana.20808","article-title":"LRRK2 expression linked to dopamine-innervated areas","volume":"59","author":"Galter","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-014-0284-z_bib133","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.neuroscience.2006.01.017","article-title":"Anatomical localization of leucine-rich repeat kinase 2 in mouse brain","volume":"139","author":"Melrose","year":"2006","journal-title":"Neuroscience"},{"key":"10.1007\/s13311-014-0284-z_bib134","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1471-4159.2006.03919.x","article-title":"Distribution of PINK1 and LRRK2 in rat and mouse brain","volume":"98","author":"Taymans","year":"2006","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-014-0284-z_bib135","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/01.jnen.0000235121.98052.54","article-title":"LRRK2 expression in normal and pathologic human brain and in human cell lines","volume":"65","author":"Miklossy","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1007\/s13311-014-0284-z_bib136","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.parkreldis.2010.08.018","article-title":"A comparative study of Lrrk2 function in primary neuronal cultures","volume":"16","author":"Dachsel","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-014-0284-z_bib137","doi-asserted-by":"crossref","first-page":"16140","DOI":"10.1074\/jbc.M111.234005","article-title":"Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2)","volume":"286","author":"Chan","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-014-0284-z_bib138","doi-asserted-by":"crossref","first-page":"e30834","DOI":"10.1371\/journal.pone.0030834","article-title":"LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth","volume":"7","author":"Kawakami","year":"2012","journal-title":"PLoS One"},{"key":"10.1007\/s13311-014-0284-z_bib139","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.parkreldis.2012.03.024","article-title":"LRRK2 I2020T mutation is associated with tau pathology","volume":"18","author":"Ujiie","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-014-0284-z_bib140","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1471-4159.2008.05217.x","article-title":"Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells","volume":"105","author":"Plowey","year":"2008","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-014-0284-z_bib141","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/ana.21019","article-title":"Localization of LRRK2 to membranous and vesicular structures in mammalian brain","volume":"60","author":"Biskup","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-014-0284-z_bib142","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1093\/hmg\/ddp346","article-title":"LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model","volume":"18","author":"Alegre-Abarrategui","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0284-z_bib143","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1093\/hmg\/ddr573","article-title":"Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning","volume":"21","author":"Dodson","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0284-z_bib144","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ajhg.2011.06.008","article-title":"A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease","volume":"89","author":"Zimprich","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-014-0284-z_bib145","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ajhg.2011.06.001","article-title":"VPS35 mutations in Parkinson disease","volume":"89","author":"Vilarino-Guell","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-014-0284-z_bib146","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.bbrc.2013.10.159","article-title":"Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic\/lysosomal response to starvation","volume":"441","author":"Manzoni","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1007\/s13311-014-0284-z_bib147","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.cub.2007.01.074","article-title":"LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins","volume":"17","author":"Sakaguchi-Nakashima","year":"2007","journal-title":"Curr Biol"},{"key":"10.1007\/s13311-014-0284-z_bib148","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1126\/science.270.5244.1999","article-title":"The ARF1 GTPase-activating protein: zinc finger motif and Golgi complex localization","volume":"270","author":"Cukierman","year":"1995","journal-title":"Science"},{"key":"10.1007\/s13311-014-0284-z_bib149","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ceb.2004.06.009","article-title":"COP and clathrin-coated vesicle budding: different pathways, common approaches","volume":"16","author":"McMahon","year":"2004","journal-title":"Curr Opin Cell Biol"},{"key":"10.1007\/s13311-014-0284-z_bib150","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.neuron.2009.11.006","article-title":"Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein","volume":"64","author":"Lin","year":"2009","journal-title":"Neuron"},{"key":"10.1007\/s13311-014-0284-z_bib151","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1073\/pnas.1318306111","article-title":"Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease","volume":"111","author":"Beilina","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-014-0284-z_bib152","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/j.yexcr.2008.02.015","article-title":"LRRK2 regulates synaptic vesicle endocytosis","volume":"314","author":"Shin","year":"2008","journal-title":"Exp Cell Res"},{"key":"10.1007\/s13311-014-0284-z_bib153","doi-asserted-by":"crossref","first-page":"141ra90","DOI":"10.1126\/scitranslmed.3003985","article-title":"Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease","volume":"4","author":"Cooper","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1007\/s13311-014-0284-z_bib154","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nbd.2013.10.013","article-title":"LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: Reversal by gene correction","volume":"62","author":"Sanders","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-014-0284-z_bib155","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e3181ff9685","article-title":"Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2","volume":"75","author":"Mortiboys","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-014-0284-z_bib156","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2174\/187152711797247858","article-title":"Kinases as targets for Parkinson's disease: from genetics to therapy","volume":"10","author":"Vancraenenbroeck","year":"2011","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1007\/s13311-014-0284-z_bib157","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1021\/cb2002413","article-title":"Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons","volume":"6","author":"Ramsden","year":"2011","journal-title":"ACS Chem Biol"},{"key":"10.1007\/s13311-014-0284-z_bib158","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nchembio.538","article-title":"Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2","volume":"7","author":"Deng","year":"2011","journal-title":"Nat Chem Biol"},{"key":"10.1007\/s13311-014-0284-z_bib159","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1021\/cn200117j","article-title":"Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models","volume":"3","author":"Kramer","year":"2012","journal-title":"ACS Chem Neurosci"},{"key":"10.1007\/s13311-014-0284-z_bib160","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1021\/ml300123a","article-title":"Brain penetrant LRRK2 inhibitor","volume":"3","author":"Choi","year":"2012","journal-title":"ACS Med Chem Lett"},{"key":"10.1007\/s13311-014-0284-z_bib161","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1016\/j.bmcl.2013.05.054","article-title":"Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2","volume":"23","author":"Troxler","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1007\/s13311-014-0284-z_bib162","doi-asserted-by":"crossref","first-page":"9416","DOI":"10.1021\/jm301020q","article-title":"Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors","volume":"55","author":"Estrada","year":"2012","journal-title":"J Med Chem"},{"key":"10.1007\/s13311-014-0284-z_bib163","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.neuroscience.2007.10.062","article-title":"Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson's disease","volume":"152","author":"Westerlund","year":"2008","journal-title":"Neuroscience"},{"key":"10.1007\/s13311-014-0284-z_bib164","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1741-7015-10-20","article-title":"Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?","volume":"10","author":"Rudenko","year":"2012","journal-title":"BMC Med"},{"key":"10.1007\/s13311-014-0284-z_bib165","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tips.2012.04.001","article-title":"Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease","volume":"33","author":"Lee","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"10.1007\/s13311-014-0284-z_bib166","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nn.2372","article-title":"Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss","volume":"12","author":"Tain","year":"2009","journal-title":"Nat Neurosci"},{"key":"10.1007\/s13311-014-0284-z_bib167","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ajhg.2011.08.009","article-title":"Translation initiator EIF4G1 mutations in familial Parkinson disease","volume":"89","author":"Chartier-Harlin","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-014-0284-z_bib168","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1749-6632.2009.05118.x","article-title":"The progression of pathology in Parkinson's disease","volume":"1184","author":"Halliday","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1007\/s13311-014-0284-z_bib169","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1741-7015-6-32","article-title":"The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study","volume":"6","author":"Latourelle","year":"2008","journal-title":"BMC Med"},{"key":"10.1007\/s13311-014-0284-z_bib170","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1212\/01.wnl.0000254483.19854.ef","article-title":"Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease","volume":"68","author":"Goldwurm","year":"2007","journal-title":"Neurology"},{"key":"10.1007\/s13311-014-0284-z_bib171","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.neuron.2012.08.022","article-title":"LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis","volume":"75","author":"Matta","year":"2012","journal-title":"Neuron"},{"key":"10.1007\/s13311-014-0284-z_bib172","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1471-4159.2012.07809.x","article-title":"Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein","volume":"122","author":"Niu","year":"2012","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-014-0284-z_bib173","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/hmg\/dds003","article-title":"LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1","volume":"21","author":"Wang","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0284-z_bib174","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1074\/jbc.M113.507913","article-title":"A direct interaction between leucine-rich repeat kinase 2 and specific beta-tubulin isoforms regulates tubulin acetylation","volume":"289","author":"Law","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-014-0284-z_bib175","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00018-012-1061-y","article-title":"The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK\/ERK pathway","volume":"70","author":"Bravo-San Pedro","year":"2013","journal-title":"Cell Mol Life Sci"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-014-0284-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-014-0284-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923016203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923016203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-014-0284-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:06:16Z","timestamp":1761807976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923016203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":175,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1878747923016203"],"URL":"https:\/\/doi.org\/10.1007\/s13311-014-0284-z","relation":{},"ISSN":["1878-7479"],"issn-type":[{"type":"print","value":"1878-7479"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneity of Leucine-Rich Repeat Kinase 2 Mutations: Genetics, Mechanisms and Therapeutic Implications","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-014-0284-z","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}